Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Windgap and its manufacturing partners are commercializing its ANDI® wet/dry autoinjector platforms. The first product using this platform will be epinephrine for the treatment of anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Taiwania Capital
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 07, 2021